AYED AYED, MD

BIOGRAPHY

Dr. Ayed Ayed is board-certified in medical oncology, hematology, and internal medicine and practices at our Riverside and Northside locations. Dr. Ayed originally grew up in Palestine and received his Doctor of Medicine degree from the University of Jordan.

His first home in the United States was Gainesville, FL, where he lived for three years while completing his residency at the University of Florida. After completing his fellowship at the Mayo Clinic in Rochester, MN, Dr. Ayed returned to the region he fell in love with during his residency: North Florida.

While in high school, Dr. Ayed’s uncle was diagnosed with cancer. “His experience showed me how inadequate control of symptoms and lack of information can lead to anxiety and suffering,” he shares. This experience, combined with his love of science and biology, led him to a career in medicine and oncology, and taught him invaluable ways to assist patients. “Through witnessing my uncle’s experience, I learned that good communication and symptom management are paramount. This is something I try to emphasize with all of my patients,” he says. Dr. Ayed further adds, “my philosophy when it comes to helping patients is that keeping them well-informed results in patients who are more empowered and confident in their treatment plan.”

Dr. Ayed loves that his jobs offers him the opportunity of finding joy through service. “Serving my patients, colleagues, and community is my greatest privilege,” he says.

In his free time, Dr. Ayed enjoys vegetarian cooking, gardening, spending time with friends and loved ones, and being in nature doing activities such as hiking and kayaking.

Happy with your care? Leave me a review!

Curriculum Vitae

LANGUAGES

English
Fluent
Spanish
Intermediate
Arabic
Fluent

BOARD CERTIFICATIONS

Hematology
Internal Medicine
Medical Oncology

PROFESSIONAL ASSOCIATIONS

American Medical Association
American Society of Clinical Oncology
American Society of Hematology
Mayo Clinic Alumni Association
Florida Medical Association

FELLOWSHIP

Mayo Clinic, Rochester
Hematology/Oncology

RESIDENCY

University of Florida

INTERNSHIP

Palestine Medical Center

EDUCATION

University of Jordan
Doctor of Medicine

HONORS AND AWARDS

University of Florida health Customer Service Key Award
University of Jordan Award for Academic Distinction

RESEARCH (Principal Investigator Responsibilities)

NCT04510129
A Multicenter Cancer Biospecimen Collection Study
NCT03764618
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
NCT04666038
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04487080
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04623775
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumba in Combination With Chemotherapy as First-Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04182204
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04057040
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients with Phlebotomy-Requiring Polycythemia Vera
NCT04076943
A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
NCT02582879
informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
NCT05254743
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) vs Ibruitinib in Patients with Chronic Clymphocytic Leukemia/Small Lymphocytic Leukemia (BRUIN-CLL-314)
NCT06350097
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants w/ Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic NSCLC
NCT06568939
A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Evaluate the Safety and Efficacy of Chemoimmunotherapy in Previously Untreated Follicular Lymphoma
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Evaluate the Safety and Efficacy of Chemoimmunotherapy in Previously Untreated Follicular Lymphoma
NCT05952024
A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma
NCT04666038
A Phase 3, Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
NCT04965493
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
NCT04623775
A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT05555732
A Randomized Phase 3 Study of Datopotamab Deruxtecan (DatoDXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or metastatic PD-L 1 TPS<50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations
NCT05450692
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti PD (L)1 Therapy and Platinum-based Chemotherapy
NCT05207670
An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy In Patients with Select B-Cell Malignancies

PUBLICATIONS

Leukemia Research
Relationship of serum imatinib trough level and response in CML patients: long term follow-up
American Journal of Clinical Pathology
Interobserver variability of mitotic index and utility of PHH3 for risk stratification in gastrointestinal stromal tumors.
Critical Reviews in Oncology/Hematology
Immunotherapy for multiple myeloma: Current status and future directions
American Journal of Hematology
Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.
Leukemia Lymphoma
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Journal of Experimental Medicine
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
American Journal of Hematology
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience
Blood Cancer Journal
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): Analysis from two phase 2 studies.
Schedule an Appointment